Infants and young children with cystic fibrosis have abnormal lungs at birth, with congenital defects of the airways, mucus glands, and airway surface liquid already apparent. Infection and inflammation are independent, yet interrelated causes of early childhood pulmonary disease, even in the absence of symptoms. Mucolytics, anti-infectives, and anti-inflammatory therapies are all challenging to implement in treatment of infants and young children for a variety of reasons. In this session, attendees will learn about the latest updates in the use of anti-infectives, mucolytics, and anti-inflammatory strategies.
Discuss the latest concepts and progress in treatment strategies for infection, inflammation, and mucus stasis.
Describe the challenges to therapeutic development and implementation of early treatment strategies in infants and young children.
Define the challenges with overcoming early inflammation as new treatments (including anti-infectives, mucolytics, and modulators) are implemented in the youngest patients.